Eli Lilly CDR (CAD Hedged)
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 27
- Registration Number
- NCT06704763
- Locations
- πΊπΈ
ICON, Salt Lake City, Utah, United States
A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 80
- Registration Number
- NCT06692348
- Locations
- π―π΅
Sumida Hospital, Sumida-ku, Tokyo, Japan
π―π΅Hakata Clinic, Fukuoka, Japan
π―π΅Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan
A Study of LY4005130 in Healthy Participants
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 140
- Registration Number
- NCT06690996
- Locations
- πΊπΈ
Fortrea Clinical Research Unit, Dallas, Texas, United States
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 275
- Registration Number
- NCT06683508
- Locations
- πΊπΈ
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona, United States
πΊπΈHOPE Research Institute, Phoenix, Arizona, United States
πΊπΈHeadlands Research - Scottsdale, Scottsdale, Arizona, United States
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 125
- Registration Number
- NCT06672939
- Locations
- πΊπΈ
Carey Chronis MD Pediatric, Infant and Adolescent Medicine, Ventura, California, United States
πΊπΈYale School of Medicine - Yale Diabetes Center (YDC)) Trials, New Haven, Connecticut, United States
πΊπΈStamford Therapeutics Consortium, Stamford, Connecticut, United States
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 125
- Registration Number
- NCT06672549
- Locations
- πΊπΈ
Carey Chronis MD Pediatric, Infant and Adolescent Medicine, Ventura, California, United States
πΊπΈYale School of Medicine - Yale Diabetes Center (YDC)) Trials, New Haven, Connecticut, United States
πΊπΈStamford Therapeutics Consortium, Stamford, Connecticut, United States
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 800
- Registration Number
- NCT06662383
- Locations
- πΊπΈ
Encompass Clinical Research, Spring Valley, California, United States
πΊπΈMedical Advancement Centers of Arizona, Tempe, Arizona, United States
πΊπΈMary & Dick Allen Diabetes Center, Newport Beach, California, United States
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 68
- Registration Number
- NCT06657768
- Locations
- πΊπΈ
Atlanta Center of Medical Research, Atlanta, Georgia, United States
πΊπΈCenExel iResearch, LLC (CenExel iRA), Decatur, Georgia, United States
πΊπΈDuke Early Phase Research Unit, Durham, North Carolina, United States
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1200
- Registration Number
- NCT06653153
- Locations
- π°π·
Hanyang University Seoul Hospital, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
π°π·Konkuk University Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
π°π·Asan Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 600
- Registration Number
- NCT06649045
- Locations
- π―π΅
Sakai City Medical Center, Sakai, Osaka, Japan
π―π΅Osaka Kaisei Hospital, Osaka, Japan
π¨π³Huzhou Central Hospital, Huzhou, Zhejiang, China